Evidence map›Paper›PMID 35326576›Full record

ArticleCancers2022

Parathyroid Carcinoma: Incidence, Survival Analysis, and Management: A Study from the SEER Database and Insights into Future Therapeutic Perspectives.

Asad Ullah, Jaffar Khan, Abdul Waheed, Nitasha Sharma, Elizabeth K Pryor, Tanner R Stumpe, Luis Velasquez Zarate, Frederick D Cason, Suresh Kumar, Subhasis Misra and 8 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 52 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Parathyroid carcinoma: epidemiology and genetics.Endocrine oncology (Bristol, England) · 2026
    Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Observational
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 1 country.

Asad UllahGeorgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.ORCID 0000-0002-9435-9625
Jaffar KhanDepartment of Pathology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Abdul WaheedDepartment of Surgery, San Joaquin General Hospital, French Camp, CA 95231, USA.ORCID 0000-0002-9992-6051
Nitasha SharmaDepartment of Surgery, San Joaquin General Hospital, French Camp, CA 95231, USA.
Elizabeth K PryorGeorgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.
Tanner R StumpeGeorgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.
Luis Velasquez ZarateGeorgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.
Frederick D CasonDepartment of Surgery, San Joaquin General Hospital, French Camp, CA 95231, USA.
Suresh KumarNational Cancer Institute, NIH, Bethesda, MD 20892, USA.
Subhasis MisraDepartment of Surgery, Brandon Regional Hospital, Brandon, FL 33511, USA.
Sravan KavuriGeorgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.
Hector MesaDepartment of Pathology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Nitin RoperNational Cancer Institute, NIH, Bethesda, MD 20892, USA.ORCID 0000-0002-6514-5468
Shahin ForoutanDepartment of Surgery, San Joaquin General Hospital, French Camp, CA 95231, USA.ORCID 0000-0002-6947-0583
Nabin Raj KarkiGeorgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.
Jaydira Del RiveroNational Cancer Institute, NIH, Bethesda, MD 20892, USA.ORCID 0000-0001-9710-4030
William F SimondsNational Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, MD 20892, USA.
Nagla Abdel KarimGeorgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA.
Augusta University · USSan Joaquin General Hospital · USNational Cancer Institute · USIndiana University School of MedicineNational Institute of Diabetes and Digestive and Kidney Diseases · US

Funding

Epigenetic and immunologic aspects of neuroendocrine cancersZIABC011989 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ROPER, NITIN · 2020 to 2025
$5.8M
Clinical Investigation of FIHP, Parathyroid Cancer & the HPT-JT SyndromeZIADK043012 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI SIMONDS, WILLIAM F · 2009 to 2025
$4.3M
6 · The paper itself

Abstract

Introduction: Parathyroid carcinoma (PC) is an extremely rare entity, with a frequency of 0.005% of all malignancies. Most data related to this rare disease are limited to case series and a few database studies. We present a large database study that aims to investigate the demographic, clinical, and pathological factors, prognosis, and survival of PC. Methods: Data of parathyroid carcinoma were extracted from the Surveillance, Epidemiology, and End Results (SEER) diagnosed between 1975 and 2016. Results: PC had a slightly higher incidence in men (52.2%, p < 0.005), the majority of cases affected Caucasians (75.4%, p < 0.005), and the mean age at diagnosis was 62 years. Histologically, 99.7% were adenocarcinomas not otherwise specified (p < 0.005), well-differentiated (p < 0.005), and 2−4 cm (p < 0.001) in size among the patients with available data. In cases with staging provided, most PC were organ-confined (36.8%, p < 0.001). Lymph nodes were positive in 25.2% of cases where lymph node status was reported. The main treatment modality was surgery (97.2%), followed by radiation alone (2%), and very few received chemotherapy alone (0.8%), p < 0.005. Five-year follow-up was available for 82.7% of the cases. Those who underwent surgery only or radiation alone had 5-year survivals of 83.8% and 72.2%, respectively (p < 0.037). Multivariable analysis identified tumor size >4 cm, age > 40 years, male sex, Caucasian race, distant spread, and poorly differentiated grade as independent risk factors for mortality (p < 0.001). Conclusion: PC is a very rare tumor mostly affecting Caucasian individuals in the fifth decade. Older age, poor histologic differentiation, and distant metastasis are associated with a worse prognosis. Surgical resection offers the best survival outcome. To better understand the pathogenesis and factors affecting survival, all PC patients should be enrolled in national and international registries.

Indexed as

cancer stagingincidencemortalityparathyroid carcinomaSEER programsurvival

Identifiers

PMID35326576
PMCPMC8946517
OpenAlexW4221131724

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.